ACHA Guidelines

Tuberculosis Screening and Targeted Testing of College and University Students

Purpose

Screening and targeted testing for tuberculosis (TB) is a key strategy for controlling and preventing infection on college and university campuses. Early detection provides an opportunity to promote the health of affected individuals through prompt diagnosis and treatment while preventing potential spread to others. Implementation of a screening and targeted testing program not only addresses this public health concern in campus communities but also contributes to the larger public health goal of reducing the burden of TB in the United States.

The intent of this document is to provide guidelines for screening the incoming student population, targeting those at increased risk for TB testing, and reviewing appropriate follow-up care for students diagnosed with latent TB infection (LTBI) or TB disease.

Definitions

In this document, “screening” refers to the process of identifying persons at high risk for TB infection and disease. Screening is conducted through a questionnaire where the student identifies any risk factors for TB infection and disease. “Testing” refers to the testing procedure for diagnosing LTBI, i.e., the Mantoux tuberculin skin test (TST) or interferon gamma release assay (IGRA).

Risks for exposure to and/or infection with M. tuberculosis have been identified through epidemiological and population-based studies (see Table 1). A sample screening questionnaire has been developed based on these risk factors (see Appendix B). It is designed for use by institutions for the incoming student population, in order to appropriately target students at risk for TB who would benefit from testing.

Refer to Table 2 for those factors that place an individual who is infected with TB at higher risk for progressing to active disease. Typically, factors are identified in individuals by health care providers in the clinic setting. Those at risk for exposure should be tested and if positive, are high priorities for treatment.

Whom to Screen

All incoming students should be screened for risk factors for TB through a screening questionnaire. The United States is primarily a low-incidence country, so most U.S.-born incoming students will not have risk factors for TB and will not need TB testing. However, international students arriving from countries or territories with an increased incidence of TB should be tested because this subpopulation has been identified epidemiologically as having a higher incidence of LTBI and an increased risk for developing active TB disease.1 While all incoming students should be screened, only those students with identifiable risk factors for exposure to TB and/or for TB disease should be tested. Incoming students at low risk should not be tested for TB. Students with a documented previous positive test should not be retested.

High-incidence areas are defined as countries or territories with an annual incidence of TB disease of greater than or equal to 20 cases per 100,000 population. Most countries in Africa, Asia, Central America, Eastern Europe, and South America are included in this group. See Appendix A for a current list of low-incidence countries and territories, as identified by the World Health Organization (WHO) Global Health Observatory.

While national trends indicate a decline in the overall number of TB cases since 1993, active disease transmission continues to occur. It is important to focus on local epidemiology to identify trends in individual states or regions. The epidemiology of TB among foreign-born populations differs considerably from area to area. To tailor TB-control efforts to local needs, TB-control programs should develop epidemiologic profiles to identify groups of foreign-born persons in their jurisdictions who are at higher risk for TB. In 2009, approximately 60% of TB cases in the United States

TABLE 1: Persons at Higher Risk for Exposure to and/or Infection with *M. tuberculosis*

- Close contacts of persons known or suspected to have active TB disease
- Foreign-born persons from areas that have a high incidence of active TB disease (e.g., Africa, Asia, Eastern Europe, Latin America, and Russia)
- Persons who visit areas with a high prevalence of TB disease, especially if visits are frequent or prolonged
- Residents and employees of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)
- Health care workers who serve clients who are at increased risk for active TB disease
- Populations defined locally as having an increased incidence of latent *M. tuberculosis* infection or active TB disease, possibly including medically underserved, low-income populations, or persons who abuse drugs or alcohol
- Infants, children, and adolescents exposed to adults who are at increased risk for latent tuberculosis infection or active TB disease


TABLE 2: Persons at Increased Risk for Progression of LTBI to TB Disease

- Persons infected with HIV
- Children younger than 5 years of age
- Persons who were recently infected with *M. tuberculosis* (within the past 2 years)
- Persons with a history of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Persons who are receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
- Persons with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
- Persons who have had a gastrectomy or jejunoileal bypass
- Persons who weigh less than 90% of their ideal body weight
- Cigarette smokers and persons who abuse drugs and/or alcohol
- Populations defined locally as having an increased incidence of disease due to *M. tuberculosis*, including medically underserved, low-income populations.


occurred in foreign-born individuals. The majority of U.S. cases among foreign-born individuals are in people from seven countries (Mexico, Philippines, Vietnam, India, China, Haiti, and Guatemala). For a list of high burden countries and their profiles, see the Stop TB Partnership website at www.stoptb.org/countries/tbdata.asp.

Continuing students should be tested only when their activities place them at risk for a new infection or to meet an academic programmatic requirement. While it would be welcomed, no evidence-based data exists that identifies the amount of time spent in a given high-risk country that constitutes significant exposure. Students should discuss the specific travel circumstances with a health care provider who can determine the appropriate evaluation.²

Activities that may result in increased risk of exposure to TB may include, but are not limited to, volunteering, conducting research, mentoring, studying abroad, traveling, visiting relatives, or employment which may involve close contact with individuals in areas with increased incidence of TB whether domestically or internationally. Sponsors of these programs or health

care providers caring for these students prior to the activity should educate students of this risk and recommend testing 8 to 10 weeks after leaving the high-incidence area.

Health profession students, whether incoming or continuing, should be tested annually.

In the clinical setting, health care providers are encouraged to identify students who are at increased risk of LTBI or TB disease through screening and to test students at risk using tuberculin skin test (TST) or interferon gamma release assays (IGRA) as part of a routine evaluation.

**When to Screen and Test**

TB screening should occur by questionnaire prior to arrival on campus in conjunction with verification of pre-matriculation immunization requirements. TB testing of high-risk students only should take place no sooner than six months prior to college entrance and should be completed by the second quarter/semester registration.

**How to Test**

**Tuberculin Skin Test (TST)**

At the present time, the Mantoux test is the only acceptable TST. To perform this test, inject 0.1 ml of purified protein derivative (PPD) tuberculin containing 5 tuberculin units (TU) intradermally into the volar (inner) surface of either forearm.

While cross-reactivity between PPD and bacillus Calmette-Guerin (BCG) vaccine is possible, a history of BCG vaccination should **not** preclude tuberculin skin testing of students. However, testing with an IGRA, which does not cross-react with BCG, may be preferable to using PPD in students with a history of BCG vaccination, if feasible.

TST can be administered during pregnancy.

If a student has recently received a live virus vaccination, skin testing should be delayed for 4-6 weeks after the student received the vaccination. However, a TST can be performed on the same day as live virus administration without compromising the integrity of the result.

Two-step testing is particularly important and should be considered for the initial skin testing of persons who will be retested periodically, e.g., all health profession students, workers, and volunteers. Two-step testing is more reliable in identifying remote infection (e.g., infection in childhood). If the first test is positive, the person should be considered infected. If the first test is negative, a repeat test should be administered 1-3 weeks later. If the second test is positive, consider the person infected. If there is documentation of a negative TST within the prior 12 months, only one TST needs to be done, and this is considered the second of the two-step tests.

**Interferon Gamma Release Assays (IGRAs)**

At the present time, the IGRA method may be used in all circumstances in which the TST is currently used. The U.S. Centers for Disease Control and Prevention (CDC) TB infection control guidelines indicate that IGRAs should be used with caution in immunocompromised patients as this method has not been studied extensively in this group.

In direct comparisons, the sensitivity of the IGRA is similar to that of TST in infected persons with culture-positive TB. The IGRAs are thought to be more specific than the TST because they do not cross-react to BCG vaccine or to many commonly encountered nontuberculous mycobacteria. IGRAs may be preferred for testing persons who have received BCG and persons unlikely to return for TST reading.

Because many persons who are at high risk for TB infection come from areas of the world for which BCG is routinely used, a task force composed of the CDC, the American Thoracic Society, and the Infectious Diseases Society of America advises that all persons from high incidence countries be regarded as having taken BCG.

Multiple additional recommendations provided address quality control, test selection, and medical management after testing.

Although routine testing with both TST and IGRA is not recommended, there are situations when results from both tests may be useful.

- When the initial test is **negative** and
  - high risk for infection, progression to disease, and poor outcome (e.g., persons with HIV) are increased.

---


clinical suspicion for TB disease and confirmation of *M. tuberculosis* infection is desired; in this case having a positive result from the second test as evidence of infection increases detection sensitivity.

- When the initial test is positive and
  - additional evidence of infection is required to encourage acceptance and adherence (e.g., in foreign-born persons who attribute a positive TST to prior BCG vaccination).

Two-step testing is not needed with IGRAs. As with TST, IGRA testing should be performed on the same day as, or four weeks after, the administration of a live-virus vaccine.

### How to Interpret the TST

The TST should be read 48 to 72 hours after injection of PPD by measuring the transverse diameter of the induration across the forearm, perpendicular to the long axis. Redness or bruising is not measured.

The results are recorded in millimeters (mm) of induration. If no induration is present, “0 mm” is recorded.

Interpretation of the TST depends on both the millimeters of induration and the factors related to risk of exposure to TB disease and risk for progression to TB disease once infected.

#### >5mm is positive in the following:

- recent contacts of persons with infectious TB disease.
- persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease.
- organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 mg/d of prednisone for >1 month).
- HIV-infected persons.

#### >10mm is positive in the following:

- recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* amount of time.
- injection drug users.
- mycobacteriology laboratory personnel.
- residents, employees, or volunteers in high-risk congregate settings.
- persons with medical conditions that increase the risk of progression to TB disease including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

#### >15mm is positive in the following:

- persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.

*The significance of the exposure should be discussed with a health care provider and evaluated.

### What to Do When the TST or IGRA Is Positive

Persons with a positive TST or IGRA must undergo chest radiography and medical exam. If any x-ray changes or signs and symptoms of active TB are identified, active TB disease must be excluded.

If the chest x-ray and medical exam are normal, treatment for LTBI should be recommended since this greatly reduces the risk of TB infection progressing to TB disease in the student and serves to reduce the burden of TB in the U.S. HIV testing is recommended for all LTBI patients, unless the patient declines (opt-out screening). Treatment is most important for those with a particularly high risk for progression from latent infection to active disease including individuals who had a TST conversion within two years and those with HIV/AIDS or other clinical conditions associated with suppressed immunity (see Table 2).

Treatment with isoniazid (INH) daily for nine months is the preferred regimen; however, other regimens may be appropriate. A four-month course of Rifampin is also efficacious. A shorter course using INH plus rifapentine once weekly for three months under directly observed therapy (DOT) or self-administered can be used for select patients.

Short course therapy offers a potential advantage for students to complete treatment within a single semester.

---


Consultation with the local or state health department or an infectious disease specialist is recommended. Note: rifapentine should not be used in pregnancy and may reduce the effectiveness of hormonal contraception.

Completion of treatment should be a high priority and should be supported by providing education in the student's primary language, insuring confidentiality, offering incentives to mark treatment milestones, and case management by a culturally competent health care provider to build trust and gain buy-in.

Baseline laboratory monitoring of ALT, AST, and bilirubin during treatment of LTBI is indicated only for students

- with a history of liver disorder.
- with a risk of chronic liver disease.
- who regularly use alcohol.
- with HIV infection.
- who are pregnant or up to three months postpartum.

Students with baseline abnormal liver function tests should be monitored at regular intervals with clinical and laboratory evaluation. Testing may be considered on an individual basis, particularly in those taking medications for chronic medical conditions.

All others receiving treatment for LTBI need only monthly review of symptoms to monitor for medication side effects.

Post-treatment follow-up should include providing the student documentation of TST or IGRA results, chest radiograph results, and the dosage and duration of medication treatment. Students who have completed LTBI therapy, as well as those who elected not to take therapy, should be educated regarding signs and symptoms of TB disease and instructed to seek medical care immediately upon developing any of the signs or symptoms of TB.

Additional Resources (in addition to footnotes)
ATS/CDC/IDSA. Treatment of Tuberculosis. MMWR June 2003; 52 (No. RR-11).


APPENDIX A

“Low Incidence” Areas with Estimated or Reported Tuberculosis Incidence, 2017

“Low Incidence” areas are defined as areas with reported or estimated incidence of <20 cases per 100,000 population.

<table>
<thead>
<tr>
<th>Country</th>
<th>Country</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Samoa</td>
<td>Finland</td>
<td>Saint Kitts and Nevis</td>
</tr>
<tr>
<td>Andorra</td>
<td>France</td>
<td>Saint Lucia</td>
</tr>
<tr>
<td>Antigua and Barbuda</td>
<td>Germany</td>
<td>Saint Vincent and the Grenadines</td>
</tr>
<tr>
<td>Aruba</td>
<td>Greece</td>
<td>Samoa</td>
</tr>
<tr>
<td>Australia</td>
<td>Grenada</td>
<td>San Marino</td>
</tr>
<tr>
<td>Austria</td>
<td>Hungary</td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>Bahamas</td>
<td>Iceland</td>
<td>Seychelles</td>
</tr>
<tr>
<td>Bahrain</td>
<td>Iran (Islamic Republic of)</td>
<td>Serbia</td>
</tr>
<tr>
<td>Barbados</td>
<td>Ireland</td>
<td>Sint Maarten (Dutch part)</td>
</tr>
<tr>
<td>Belgium</td>
<td>Israel</td>
<td>Slovakia</td>
</tr>
<tr>
<td>Bermuda</td>
<td>Italy</td>
<td>Slovenia</td>
</tr>
<tr>
<td>Bonaire, Saint Eustatius and Saba</td>
<td>Jamaica</td>
<td>Spain Sweden</td>
</tr>
<tr>
<td>British Virgin Islands</td>
<td>Japan</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Canada</td>
<td>Jordan</td>
<td>Syrian Arab</td>
</tr>
<tr>
<td>Cayman Islands</td>
<td>Lebanon</td>
<td>Republic</td>
</tr>
<tr>
<td>Chile</td>
<td>Luxembourg</td>
<td>The Former Yugoslav Republic of Macedonia</td>
</tr>
<tr>
<td>Cook Islands</td>
<td>Malta</td>
<td>Tokelau</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>Mauritius</td>
<td>Tonga</td>
</tr>
<tr>
<td>Croatia Cuba</td>
<td>Monaco</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>Curacao</td>
<td>Montenegro</td>
<td>Turkey</td>
</tr>
<tr>
<td>Cyprus</td>
<td>Montserrat</td>
<td>Turks and Caicos Islands</td>
</tr>
<tr>
<td>Czechia</td>
<td>Netherlands</td>
<td>United Arab Emirates</td>
</tr>
<tr>
<td>Denmark</td>
<td>New Zealand</td>
<td>United Kingdom of Great Britain and Northern Ireland</td>
</tr>
<tr>
<td>Dominica</td>
<td>New Caledonia</td>
<td>United States of America</td>
</tr>
<tr>
<td>Egypt</td>
<td>Norway</td>
<td>US Virgin Islands</td>
</tr>
<tr>
<td>Estonia</td>
<td>Oman Poland</td>
<td>Wallis and Futuna Islands</td>
</tr>
<tr>
<td></td>
<td>Puerto Rico</td>
<td>West Bank and Gaza Strip</td>
</tr>
</tbody>
</table>


APPENDIX B

Tool for Institutional Use

Part I: Tuberculosis (TB) Screening Questionnaire (to be completed by incoming students)

Please answer the following questions:

Have you ever had close contact with persons known or suspected to have active TB disease? □ Yes □ No

Were you born in one of the countries or territories listed below that have a high incidence of active TB disease? (If yes, please CIRCLE the country, below)

- Afghanistan
- Albania
- Algeria
- Angola
- Anguilla
- Argentina
- Armenia
- Azerbaijan
- Bangladesh
- Belarus
- Belize
- Benin
- Bhutan
- Bolivia (Plurinational State of)
- Bosnia and Herzegovina
- Botswana
- Brazil
- Brunei Darussalam
- Bulgaria
- Burkina Faso
- Burundi
- Cabo Verde
- Cambodia
- Cameroon
- Central African Republic
- Chad
- China
- China, Hong Kong SAR
- China, Macao SAR
- Colombia

Comoros
Congo
Côte d’Ivoire
Democratic People's Republic of Korea
Democratic Republic of the Congo
Djibouti
Dominican Republic
Ecuador
El Salvador
Equatorial Guinea
Eritrea
Ethiopia
Fiji
French Polynesia
Gabon
Gambia
Georgia
Ghana
Greenland
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
India
Indonesia
Iraq
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lesotho
Liberia
Libya
Lithuania
Madagascar
Malawi
Malaysia
Maldives
Mali
Marshall Islands
Mauritania
Mexico
Micronesia (Federated States of)
Mongolia
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Nicaragua
Niger
Nigeria
Niue
Northern Mariana Islands
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Portugal
Qatar
Republic of Korea
Republic of Moldova
Romania
Russian Federation
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
Singapore
Somalia
South Africa
South Sudan
Sri Lanka
Sudan
Suriname
Swaziland
Tajikistan
Tanzania (United Republic of)
Thailand
Timor-Leste
Togo
Tunisia
Turkmenistan
Tuvalu
Uganda
Ukraine
Uruguay
Uzbekistan
Vanuatu
Venezuela (Bolivarian Republic of)
Viet Nam
Senegal
Sierra Leone
Singapore
Solomon Islands


Have you had frequent or prolonged visits* to one or more of the countries or territories listed above with a high prevalence of TB disease? (If yes, CHECK the countries or territories, above) □ Yes □ No

Have you been a resident and/or employee of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)? □ Yes □ No

Have you been a volunteer or health care worker who served clients who are at increased risk for active TB disease? □ Yes □ No

Have you ever been a member of any of the following groups that may have an increased incidence of latent *M. tuberculosis* infection or active TB disease: medically underserved, low-income, or abusing drugs or alcohol? □ Yes □ No

If the answer is YES to any of the above questions, [insert your college/university name] requires that you receive TB testing as soon as possible but at least prior to the start of the subsequent semester).

If the answer to all of the above questions is NO, no further testing or further action is required.

* The significance of the travel exposure should be discussed with a health care provider and evaluated.
Part II. Clinical Assessment by Health Care Provider

Clinicians should review and verify the information in Part I. Persons answering YES to any of the questions in Part I are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

History of a positive TB skin test or IGRA blood test? (If yes, document below)  Yes____  No____
History of BCG vaccination? (If yes, consider IGRA if possible.)  Yes____  No____

1. TB Symptom Check

Does the student have signs or symptoms of active pulmonary tuberculosis disease? Yes No____
If No, proceed to 2 or 3
If yes, check below:
- Cough (especially if lasting for 3 weeks or longer) with or without sputum production
- Coughing up blood (hemoptysis)
- Chest pain
- Loss of appetite
- Unexplained weight loss
- Night sweats
- Fever

Proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

2. Tuberculin Skin Test (TST)

(TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write “0”. The TST interpretation should be based on mm of induration as well as risk factors.)*

<p>| Date Given: | Date Read: |</p>
<table>
<thead>
<tr>
<th>M D Y</th>
<th>M D Y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result: mm of induration</td>
<td>**Interpretation: positive____ negative____</td>
</tr>
</tbody>
</table>

**Interpretation guidelines

>5 mm is positive:
- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
- Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 mg/d of prednisone for >1 month.)
- HIV-infected persons

>10 mm is positive:
- Recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* amount of time
- Injection drug users
- Mycobacteriology laboratory personnel
- Residents, employees, or volunteers in high-risk congregate settings
- Persons with medical conditions that increase the risk of progression to TB disease including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

>15 mm is positive:
- Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.

*The significance of the travel exposure should be discussed with a health care provider and evaluated.
3. Interferon Gamma Release Assay (IGRA)

Date Obtained: ____/____/____ (specify method) QFT-GIT T-Spot other____

M      D      Y

Result: negative___ positive___ indeterminate___ borderline___ (T-Spot only)

Date Obtained: ____/____/____ (specify method) QFT-GIT T-Spot other____

M      D      Y

Result: negative___ positive___ indeterminate___ borderline___ (T-Spot only)

4. Chest x-ray: (Required if TST or IGRA is positive)

Date of chest x-ray: ____/____/____ Result: normal____ abnormal____

M      D      Y

Part III. Management of Positive TST or IGRA

All students with a positive TST or IGRA with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.

- Infected with HIV
- Recently infected with M. tuberculosis (within the past 2 years)
- History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
- Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
- Have had a gastrectomy or jejunoileal bypass
- Weigh less than 90% of their ideal body weight
- Cigarette smokers and persons who abuse drugs and/or alcohol

______ Student agrees to receive treatment
______ Student declines treatment at this time

________________________________________________________________________

Health Care Professional Signature Date

________________________________________________________________________

END of SAMPLE FORM

If reproduced for use by a college or university health center, please insert your health center’s contact information.

This form should not be returned to ACHA.

Prepared originally by ACHA’s Tuberculosis Guidelines Task Force

Revised by Emerging Public Health Threats and Emergency Response Coalition